232,100 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Renaissance Technologies LLC

Renaissance Technologies LLC acquired a new stake in shares of Mural Oncology plc (NASDAQ:MURA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 232,100 shares of the company’s stock, valued at approximately $729,000. Renaissance Technologies LLC owned about 1.37% of Mural Oncology as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in MURA. BBR Partners LLC purchased a new stake in shares of Mural Oncology during the 2nd quarter valued at about $31,000. Rhumbline Advisers purchased a new position in shares of Mural Oncology in the 2nd quarter worth approximately $34,000. Dimensional Fund Advisors LP bought a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $71,000. Harbor Capital Advisors Inc. bought a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $115,000. Finally, Nicollet Investment Management Inc. bought a new stake in Mural Oncology in the second quarter worth $308,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Stock Up 1.8 %

Shares of Mural Oncology stock opened at $3.47 on Wednesday. Mural Oncology plc has a 52 week low of $2.88 and a 52 week high of $17.00. The stock’s fifty day moving average is $3.25 and its two-hundred day moving average is $3.50.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($1.90) by $0.04. As a group, research analysts predict that Mural Oncology plc will post -7.54 EPS for the current year.

Analyst Ratings Changes

MURA has been the topic of a number of analyst reports. Rodman & Renshaw initiated coverage on shares of Mural Oncology in a research report on Friday, June 28th. They set a “buy” rating and a $15.00 price objective on the stock. Raymond James initiated coverage on shares of Mural Oncology in a research report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price objective on the stock.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.